Cumberland Pharmaceuticals (CPIX) vs NeOnc Technologies (NTHI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cumberland Pharmaceuticals (CPIX) has outperformed NeOnc Technologies (NTHI) over the past year, gaining 193.5% versus a loss of 46.2%. NeOnc Technologies is the larger company by market cap ($90.9 million vs $87.6 million), about 1.0 times the size, while Cumberland Pharmaceuticals is growing revenue faster (+17.6% vs -51.8%). Cumberland Pharmaceuticals converts more of its revenue into profit, with a net margin of -6.4% versus -155404.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPIX | NTHI |
|---|---|---|
| Share price | $5.84 | $3.15 |
| Market cap | $87.57M | $90.88M |
| 1-day change | -7.30% | -9.48% |
| YTD return | +46.73% | -61.91% |
| 1-year return | +193.47% | -46.25% |
| 5-year return | +161.88% | — |
| Forward P/E | 41.71 | — |
| EPS (TTM) | $-0.57 | $-1.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.52M | $39.99K |
| Revenue growth (YoY) | +17.57% | -51.82% |
| Net income (latest FY) | $-2.84M | $-62.15M |
| Gross margin | 85.02% | — |
| Operating margin | -6.27% | -145637.52% |
| Net margin | -6.37% | -155404.38% |
| 52-week high | $9.28 | $11.38 |
| 52-week low | $2.00 | $2.50 |
| Distance from 52-week high | -37.07% | -72.31% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +439.68% |
| Average volume | 114.52K | 187.23K |
| Shares outstanding | 15.00M | 28.85M |
| Employees | 88 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CPIX has outperformed NTHI by 239.7 percentage points over the past year.
- Cumberland Pharmaceuticals is more profitable, keeping -6.4 cents of every revenue dollar as net income versus -155404.4 cents for NeOnc Technologies.
- Cumberland Pharmaceuticals grew revenue faster in its latest fiscal year (+17.57% vs -51.82%).
About Cumberland Pharmaceuticals
CPIX stock →Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
CPIX vs NTHI FAQ
Which is bigger, Cumberland Pharmaceuticals or NeOnc Technologies?
NeOnc Technologies (NTHI) is larger, with a market capitalization of $90.88M compared with $87.57M for Cumberland Pharmaceuticals (CPIX).
Which stock has performed better over the past year, CPIX or NTHI?
CPIX returned +193.47% over the past 12 months, compared with -46.25% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are Cumberland Pharmaceuticals and NeOnc Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.